1) "counseled by several industry veterans" What industry

New Post Public Reply Private Reply Replies (3) Message Board
gobears1985 longboardsurfer90210 #21252
Quote:
1) "counseled by several industry veterans" What industry veterans? He needs counseling?
Do you expect him to name names? I also don't think you understand the word counsel in this context.

2) "chief among them being patience and faith." Part of the counseling he received was an industry veteran telling him to be patient and that it takes time? Really?
I'm not getting your point. I think there are a lot of examples of patience being important and development taking time

3) "current team." You mean, whats left of the current team?
Just because a few people have left doesn't mean there is nobody left.

4) "while also delivering significant value to a healthcare system stretched to its financial capacity.” Yeah, that’s what he is concerned about.
Non-issue. Not worth commenting on. You're just nit-picking here.

5) "near-term liquidity events." Ahh- the ever so elusive near term event.
Ever so elusive until it happens, then it's not elusive anymore. It only takes one.

6) "the Board of Directors has given management the mandate to accelerate our partnering initiatives in order to acquire the resources necessary to move the rest of the portfolio forward. " Oh, so the reason we don’t have any partners for ANY OF OUR ASSETS is because management never forced us to consider them?
He said they have given the mandate to accelerate the partnering initiatives, not that they haven't ever considered it before. Also, they have more assets to partner now than they used to have.

7) "while preserving and/or transferring value to our shareholders along the way." This statement needs zero comment.
You're not providing the context of the quote. He's talking about shareholder value increasing if they partner an asset, which is obvious. So yes, there is no comment needed.

8) " transact on either ESS or Eltoprazine in order to further refine the Company’s profile into a regenerative medicine company (ESS + MANF + Phenoguard) or a neurology company (Eltoprazine + MANF + Phenoguard)" In other words, we have no idea who we are or what we are about. And what the hell does “transact on” mean?
Sell or partner. Read it carefully. If we sell ESS, we keep Elto. If we sell Elto, we keep ESS. It's not about not knowing who we are. It's about our options after we sell one of the assets involved.

9) "could provide a pipeline for a very valuable standalone public company." There is the elusive “could provide” but hasn’t yet, but keep holding your breath.
If it was already provided, this blog would not have been necessary because we'd all be rich. Just because it hasn't happened, doesn't mean it can't happen.

10) "conditions in the market for our common shares rapidly deteriorated in the third quarter." -It just gets better. Conditions in the market didn’t deteriorate the value, getting into bed with toxic financiers did. This was the one I was REALLY hoping to not hear. The CEO is directly responsible for the deterioration of the share price….PERIOD! Nice try Gerald, by passing the buck.
Discounting the market conditions and placing 100% of the blame on the CEO is ludicrous. I'm not saying the market conditions were 100% of the problem either, but no one person or situation is 100% responsible.

11) "value appreciation of our common stock could potentially occur." – Again, been hearing that for the last 3 years.
Just because it hasn't happened doesn't mean it can't happen

12) "As we evaluate potential business development opportunities." What potential business development opportunities do they have to evaluate? Been hearing this one forever. Must be attached to those ever elusive NDA’s.
Good question on your part. If you really expect specific details, you don't know how things work.

13) "we are working behind the scenes to understand." – In other words, “ we don’t know what’s going on.” That’s a great place to be after destroying all of the long term shareholders value.
Stop taking quotes out of context. He's referring to their course of action regarding the ODD pathway for Elto. It's likely they don't know yet, which is entirely reasonable.

14) "begin evaluating Phase 3 development plans for adult ADHD as well as Phase 2 development plans for Alzheimer’s aggression." - “Begin evaluating”? Means nothing.
You have to plan before you can start a trial.

15) "Given the recent uptick in interest in Alzheimer’s therapies" – Recent? The interest in Alzheimers therapies is not “recent”.
I think he's referring to AVXL here.

16) "we are especially excited about the potential to develop Eltoprazine in this area" – Ahhhhh. The overly used “especially excited”.
Nit-picking again. Do you want him to say they are not excited?

17) "made good progress on the commercial launch plan for MSPrecise® at a meeting we held in Dallas, TX." Ahhhh, the overly used “made good progress” statement. Meeting with who? Who wants MS Precise? We have had it for how long?
You're not going to find this out until it's sold.

18) " continuing to evaluate the next set of studies to further enhance LymPro’s value - Ahhhh, the “continuing to evaluate” statement. I thought this thing was going to be generating revenue so that we would not have to dilute. Besides, “a reverse split may not even be necessary.”
Go back to the Lympro blog by Dr. Trzepacz and refresh your memory

19) "and will forego the option agreement with Georgetown University." – Hence, “we have no more money to continue with our option agreement.” I thought this was necessary to strengthen the diagnostics suite and increase the accuracy of the Lympro test?
They are studying Lympro in conjuction with PET. I don't think they want to put money into advancing G'town if they are going to sell Lympro off in the near future.

20) "that we recently completely enrollment." - A fricken spelling error? Does not anyone re-read these things before they post them?
This time, I agree with you. That bugs me.

21) "we believe we have sufficient critical mass." – And again the “we believe”. Obviously the market does not share your belief.
The market doesn't believe until it does believe. It doesn't mean it won't happen

22) "are now focused on the CLIA launch plans for these products. – I thought this was going to happen ages ago. “Now focused”?
Plans change.

23) "We remain on track to transact on the diagnostics division"- Really? Remain on track? That’s a subjective term. For when? 2030?
STOP QUOTING PORTIONS OF SENTENCES. Literally, the next words were "in the fourth quarter." Geez.

24) "as a key time to potentially make public announcements of definitive agreements." – This is the best. “Potentially make” and “definitive agreements” used in the same sentence.
He can't say exactly when announcements will come if he doesn't know when agreements will be final. At least he gives a ballpark estimate of a date and time.

25) "we believe the sheer strength of our portfolio will allow the Company to overcome the challenges we face." – Yeah, its doing such a good job so far. The only challenge we need to overcome is to figure out how to get someone in there that knows what they are doing.
GC's not going anywhere so you might as well stop thinking about it.

26) "we believe we have a strong execution plan, with achievable milestones" – “Believe”? How about “know”? Also, heard this many times in the past.
Semantics. Nit-picking again.

27)"We believe the support of our shareholders at this time in our corporate history is paramount." – This one takes the trophy! And we should support you because? Based on this piece of crap blog? Based on all of things you have claimed that never happened? Your stellar communication? It’s as if he does not even realize that many of us are down 90% +. He has given us zero reason to support his, what I now consider, delusional visions.
Then don't support them and sell your shares. Easy solution.

28) "working with our team" – what team? Who is left?
I already responded to this one earlier. See #3.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 6

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 3

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 6

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Dynamics of Ross Stores Inc's Short Interest

Updated Category News Views 158

Analyzing Ross Stores Inc's Short Interest Trends Ross Stores Inc (NYSE: ROST) has recently seen a noteworthy increase in its short interest, which is currently reported at a level 3.45% higher than the previous period. Specifically, there are now approximately 6.76 million shares sold short, accounting for about 2.1% of the overall shares available for trading. The rise...

Continue Reading
Investors Urged to Consider Participation in Class Action for MTCH

Updated Category News Views 304

Investors Encouraged to Act on Class Action for Match Group The Rosen Law Firm is launching an investigation into Match Group, Inc. (NASDAQ: MTCH) on behalf of shareholders who might have suffered losses due to potential misinformation issued by the company. This inquiry arises from concerns that Match Group provided business details that may not accurately reflect its...

Continue Reading
Honkarakenne Oyj's Recent Manager Transactions Explained

Updated Category News Views 93

Honkarakenne Oyj's Manager Transactions Overview Honkarakenne Oyj is making headlines with its latest manager transactions, a reflection of the company's dynamic leadership and commitment to growth. Recently, several key transactions were reported, shedding light on the activities of management within the company. The Managers Behind the Transactions Petri Perttula's...

Continue Reading
Energiekontor Undertakes Management of New Wind Park in Scotland

Updated Category News Views 40

Energiekontor's New Chapter in Renewable Energy Energiekontor AG has taken a significant step in advancing its renewable energy portfolio with the launch of operations at the Scottish Pines Burn wind park. This facility has been a focal point since its sale to Capital Dynamics, a transaction that paved the way for Energiekontor to leverage its expertise in managing...

Continue Reading
Inspira Enterprise Welcomes Abdul Wahab Mohammed as New CEO

Updated Category News Views 243

Inspira Enterprise Announces Abdul Wahab Mohammed as CEO Inspira Enterprise, a leading global provider of cybersecurity services, has made a significant appointment with the joining of Abdul Wahab Mohammed as its new CEO for the Middle East and Africa (MEA) region. This strategic move is aimed at bolstering the company’s growth ambitions across these key markets....

Continue Reading